A new SEC filing for Thermo Fisher Scientific Inc. (TMO) was recorded as of 1 August 2026, prompting renewed examination of the company's financial and ownership profile [Brief - 2026-09-19]. No additional briefing disclosures beyond that filing date were available for the current reporting period [Brief - 2026-09-11]. The dual reporting cycles in September reflect ongoing monitoring of TMO's regulatory submissions, with no extraordinary corporate events disclosed in either briefing.
For the trailing twelve months ending 2026-06-27, TMO recorded revenue of $46.34 billion, representing year-over-year growth of 10.49%, with net income of $6.98 billion and a net margin of 15.07% [SEC 10-Q - TMO - 2026-06-27]. Gross margin stood at 24.45% and operating margin at 17.58%. Earnings per share grew 9.35% year-over-year. The company held $4.06 billion in cash against total debt of $45.65 billion. The price-to-earnings ratio as of the reporting date was 36.31 [SEC 10-Q - TMO - 2026-06-27].
Insider activity in September 2026 comprised 27 transactions with a net selling direction, totalling approximately -$2.54 million in net value [SEC Form 4 - TMO - 2026-09]. On the institutional side, five notable managers opened new positions in TMO during the most recent 13F reporting period: Citadel (Ken Griffin), D1 Capital (Dan Sundheim), Millennium (Izzy Englander), AQR Capital (Cliff Asness), and Bridgewater (Ray Dalio) all initiated holdings [SEC 13F - Citadel - Q2 2026] [SEC 13F - D1 Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. The concurrent entry of five institutional managers constitutes the material ownership change that triggered this report.
The prevailing macroeconomic backdrop features a 10-year US Treasury yield of 5.18% and a 2-year yield of 4.87%, producing a normal yield curve spread of 31 basis points [FRED DGS10] [FRED DGS2]. TMO carries a substantial debt load of $45.65 billion, making the current interest rate environment a relevant factor in assessing its financing costs against reported cash of $4.06 billion [SEC 10-Q - TMO - 2026-06-27].